title: Novel molecular platform integrated iron chelation therapy for 1H-MRI detection of β-galactosidase activity.
abstract: Targeting the increased Fe(3+) content in tumors, we propose a novel molecular platform integrated cancer iron chelation therapy for (1)H-magnetic resonance imaging (MRI) detection of β-galactosidase (β-gal) activity. Following this idea, we have designed, synthesized, and characterized a series of β-d-galactosides conjugated with various chelators and demonstrated the feasibility of this concept for assessing β-gal activity in solution by (1)H-MRI T1 and T2 relaxation mapping.
authors: Xinjiang Institute of Medicinal Development, Chinese Academy of Medical Sciences, 9 Xinming Road, Urumqi, Xinjiang 830002, China.
authors: Xiaojin
authors: X
authors: Li
authors: Zhongwei
authors: Z
authors: Zhang
authors: Zijun
authors: Z
authors: Yu
authors: Jennifer
authors: J
authors: Magnusson
authors: Jian-Xin
authors: JX
authors: Yu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015415:Biomarkers / Q000378:metabolism; D002614:Chelating Agents / Q000737:chemistry; D015913:Chelation Therapy / Q000379:methods*; D003124:Colorimetry; D006801:Humans; D006868:Hydrolysis; D007501:Iron / Q000737:chemistry / Q000494:pharmacology*; D007700:Kinetics; D007763:Lac Operon; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008956:Models, Chemical; D009369:Neoplasms / Q000188:drug therapy*; D001616:beta-Galactosidase / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D002614:Chelating Agents; D007501:Iron; D001616:beta-Galactosidase